Protara Therapeutics, Inc. (TARA) Operating income 2016–2025
Protara Therapeutics, Inc. (TARA) annual operating income history from SEC filings — each fiscal year as reported.
-$64.5MFY2025 · since FY2016: -$28.7M → -$64.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$64.5M | -31.3% |
| FY2024 | -$49.2M | -12.7% |
| FY2023 | -$43.6M | +35.0% |
| FY2022 | -$67.1M | -41.2% |
| FY2021 | -$47.5M | -37.9% |
| FY2020 | -$34.4M | -339.9% |
| FY2019 | -$7.8M | +63.4% |
| FY2018 | -$21.4M | +29.6% |
| FY2017 | -$30.4M | -5.8% |
| FY2016 | -$28.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TARA financial trends
TARA RevenueTARA Net incomeTARA Net marginTARA Gross profitTARA Gross marginTARA Operating marginTARA Operating cash flowTARA Free cash flowTARA Capital expendituresTARA Return on equityTARA Stock buybacksTARA Dividends paidTARA Total assetsTARA Total liabilitiesTARA Shareholders’ equityTARA overview →